drugset / Trial / NCT00049595
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
Phase 3
Completed
552 enrolled
European Organisation for Research and Treatment of Cancer - EORTC
Australasian Leukaemia and Lymphoma Group · collabGrup per l'Estudi dels Limfomes de Catalunya i Balears · collabLymphoma Study Association · collabLymphoma Trials Office · collabNCIC Clinical Trials Group · collabNordic Lymphoma Group · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating stage III or stage IV Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have stage III or stage IV Hodgkin's lymphoma.
Timeline
- Start
- 2002-08
- Primary completion
- 2010-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bleomycin | Unknown | — | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Comparator | Dacarbazine | Small molecule | — | Intravenous |
| Subject | Doxorubicin | Other / unclassified | — | Intravenous |
| Subject | Etoposide | Small molecule | — | Intravenous |
| Subject | Prednisone | Other / unclassified | — | Oral |
| Comparator | Vinblastine | Small molecule | — | Intravenous |
| Subject | Vincristine | Small molecule | — | Intravenous |
| Subject | procarbazine | Small molecule | — | Oral |
| Background | Pegfilgrastim | Protein / enzyme biologic | — | Subcutaneous |
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |